Skip to content
PICO Portalanswers from OpenAlex

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?

PaperCitations, authors & open-access status

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? is a paper indexed in PICO Portal from OpenAlex.

How many citations does Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? have?

PICO Portalcitation count

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? has 67 citations in the OpenAlex counts PICO Portal stores.

When was Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? published?

PICO Portalyear

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? has 2018 year in the PICO Portal index.

What is the open-access status of Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor??

PICO Portaloa status

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? has closed oa status in the PICO Portal index.

What is the DOI of Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor??

PICO Portaldoi

The DOI for Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? is on the source record.

What is the PMID of Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor??

PICO Portalpmid

The PMID for Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? is on the source record.

What is the OpenAlex record for Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor??

PICO Portalopenalex

The OpenAlex for Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial